Table 3

Crude and adjusted effects of stavudine use on toxicity initiated on HAART

Toxicity

No events

Person

Time (years)

Rate/100 pys*

(95% CI)

Crude HR§

(95% CI)

Adjusted† HR

(95% CI)


Peripheral Neuropathy

Other

d4T-based

61

1454

775.9

12055.5

7.9 (6.0-10.1)

12.1 (7.0-19.5)

1.0

1.53 (1.19-1.98)

1.0

2.02 (1.35-3.03)


Symptomatic hyperlactataemia

Other

d4T-based

12

487

852.3

13690.9

1.4 (0.7-2.5)

3.6 (1.2-7.5)

1.0

2.70 (1.52-4.79)

1.0

2.81 (1.26-6.31)


Lactic acidosis

Other

d4T-based

7

214

848.3

13805.9

0.8 (0.3-1.7)

1.6 (0.4-5.2)

1.0

2.09 (0.99-4.44)

1.0

2.55 (0.81-8.00)


Pancreatitis

Other

d4T-based

1

14

858.9

14126.2

0.1 (0.003-0.6)

0.1 (0.02-2.6)

1.0

0.95 (0.13-7.21)

1.0

0.40 (0.05-3.16)


Lipoatrophy

Other

d4T-based

25

616

834.0

13534.3

3.0 (1.9-4.4)

4.6 (2.1-9.6)

1.0

1.67 (1.12-2.50)

1.0

1.60 (0.92-2.77)


Hypertension

Other

d4T-based

17

167

845.0

13929.0

2.0 (1.2-3.2)

1.2 (0.2-4.0)

1.0

0.66 (0.40-1.08)

1.0

0.83 (0.39-1.78)


Diabetes Mellitus

Other

d4T-based

1

28

859.0

14122.7

0.1 (0.003-0.6)

0.2 (0.02-2.6)

1.0

1.90 (0.26-14.04)

1.0

2.07 (0.28-15.21)


Dyslipidaemia

Other

d4T-based

9

109

856.5

14097.2

1.1 (0.4-2.0)

0.8 (0.2-4.0)

1.0

0.82 (0.41-1.61)

1.0

0.61 (0.27-1.40)


*pys = person years

§ HR = hazard ratio estimated from Cox proportional hazard models

95% CI = 95% confidence interval

All models adjusted for age, gender, baseline CD4 count, baseline body mass index and time at which HAART was initiated (either prior to or post October 2007)

Menezes et al. BMC Infectious Diseases 2011 11:244   doi:10.1186/1471-2334-11-244

Open Data